Steven T Leach, Tess Wheeler, Nerissa Bowcock, Alan Aitchison, Daniel A Lemberg, Andrew S Day
{"title":"The emerging roles of intestinal organoid models in inflammatory bowel disease research.","authors":"Steven T Leach, Tess Wheeler, Nerissa Bowcock, Alan Aitchison, Daniel A Lemberg, Andrew S Day","doi":"10.1080/17474124.2026.2635421","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The chronic immune mediated gastrointestinal disease, Inflammatory Bowel Disease (IBD), is increasing in prevalence. However, IBD pathogenesis remains unclear despite decades of research. Therefore, new methods and models of disease are required to gain further insights into IBD pathogenesis. Recent advances in stem cell culture technology now allows for the routine <i>in vitro</i> culture of stem cells derived from an individual. These <i>in vitro</i> stem cells can differentiate into cell-types and cell clusters that resemble the tissue origin of the stem cells. These cell clusters have been termed organoids.</p><p><strong>Areas covered: </strong>Following review of recent available literature, the goal of this review was to specifically focus on intestinal organoids and provide basic methodology of organoid derivation. The review will also discuss the current and potential applications of intestinal organoid models in Gastroenterology research including IBD pathogenesis, host-microbiome interactions, therapeutic response and drug discovery, very-early onset IBD, organ-on-a-chip and bioprinted models.</p><p><strong>Expert opinion: </strong>Organoids offer tangible benefits for improved patient outcomes, particularly with respect to personalized medicine approaches to IBD management.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"247-256"},"PeriodicalIF":2.5000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2026.2635421","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The chronic immune mediated gastrointestinal disease, Inflammatory Bowel Disease (IBD), is increasing in prevalence. However, IBD pathogenesis remains unclear despite decades of research. Therefore, new methods and models of disease are required to gain further insights into IBD pathogenesis. Recent advances in stem cell culture technology now allows for the routine in vitro culture of stem cells derived from an individual. These in vitro stem cells can differentiate into cell-types and cell clusters that resemble the tissue origin of the stem cells. These cell clusters have been termed organoids.
Areas covered: Following review of recent available literature, the goal of this review was to specifically focus on intestinal organoids and provide basic methodology of organoid derivation. The review will also discuss the current and potential applications of intestinal organoid models in Gastroenterology research including IBD pathogenesis, host-microbiome interactions, therapeutic response and drug discovery, very-early onset IBD, organ-on-a-chip and bioprinted models.
Expert opinion: Organoids offer tangible benefits for improved patient outcomes, particularly with respect to personalized medicine approaches to IBD management.
期刊介绍:
The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.